Categories: Innovation

Heath-tech firm produces wearable to beat pain, through non-invasive methods

CURAPOD, a Made-in-India health-tech brand backed by Litemed, has brought out a clinically validated wearable designed for effective, everyday pain relief.

Registered with the Government of India’s Central Drugs Standard Control Organization (CDSCO) and the USFDA, it stands as India’s first non-invasive personalised pain management device.

Designed for over 30 conditions, including chronic back and knee pain, arthritis, tendonitis, sports injuries and everyday strain, the device is being adopted by physiotherapy centres, wellness hubs and early consumers seeking trusted, drug-free relief, an official release claims.  

The device uses medical-grade photobiomodulation technology to deliver red and near-infrared light that promotes cellular repair, reduces inflammation, and accelerates recovery.

Its adaptive engine calibrates therapy intensity in real time based on muscle response, often providing noticeable relief within 30 minutes.

The companion mobile app personalises therapy plans, tracks progress, and monitors pain, enabling professional-grade treatment in the comfort of home.

CURAPOD, it is claimed, provides absolute drug-free therapy with no side effects and comes with a one-year warranty.

“Its adaptive system adjusts intensity based on user comfort, offering consistent and targeted pain relief,” Surya Maguluri, Founder and Chief Technology Officer, CURAPOD, said.

“This data-driven approach allows clinicians to monitor progress remotely, refine therapy programmes, and deliver measurable outcomes, making it the first wearable in India to integrate clinical precision with everyday usability,” he added.

The device is priced at ₹8,399 and can be used according to the pain condition and intensity, following defined protocols, the statement read.

It is currently available across India through their D2C website and is likely to be listed on leading marketplaces from the first quarter of 2026, with broader retail and e-commerce expansion planned over the following two years.

“From operations to delivery, we focus on building trust, accessibility, and reliability,” said Sri Velliyur, Co-Founder and CEO. “By manufacturing entirely in India and partnering with wellness chains and physiotherapy networks, we ensure the device reaches users consistently and efficiently, including in tier-2 and 3 cities. Our goal is to make clinically validated, non-invasive pain relief widely accessible without compromising on quality or affordability,” he added.

About CURAPOD

CURAPOD, backed by Litemed, is a health-tech company founded in 2022 by Sri Velliyur and Surya Maguluri to make advanced, non-invasive pain relief accessible to everyday users.

Built on medical-grade photobiomodulation technology and a proprietary adaptive engine, CURAPOD claims to deliver personalised, drug-free therapy for over 30 musculoskeletal conditions and provide noticeable relief within 30 minutes.

TBM Newsdesk

Recent Posts

Lords of the Indian Ring showcase their heft

The Pro Wrestling League (PWL), India’s franchise-based professional wrestling league sanctioned by the Wrestling Federation…

17 hours ago

A structural analysis of capacity slack in India’s manufacturing sector

On 6 February 2026, the Reserve Bank released the results of the Order Books, Inventories…

2 days ago

‘Conducive for Conductors’: India set for the big league with latest Qualcomm feat

: In a landmark achievement for India’s fast-evolving semiconductor ecosystem, Qualcomm Technologies, Inc. has successfully…

2 days ago

Decoding RBI’s recent MPC meeting, and its key decisions on digital payments

The Monetary Policy Statement was announced by the Reserve Bank of India’s Monetary Policy Committee…

3 days ago

‘JC: The University’ set to release on February 6

Kannada film ‘JC: The University’ is all set to release in theatres on February 6,…

4 days ago

BEL bags ₹581 crore in fresh defence orders

Navratna Defence Public Sector Undertaking Bharat Electronics Limited (BEL) has further reinforced its robust order…

4 days ago